(…) forms a biophysical blockade, entrapping free monosaccharides and delaying their interaction with enterocytes, producing a self-regulated release effect that attenuates glucose uptake. Simultaneously, polyphenols such as resveratrol, quercetin, and catechins inhibit α-amylase and α-glucosidase—key enzymatic mediators of polysaccharide hydrolysis—thereby attenuating glycemic load at the enzymatic level. This enzymatic inhibition delays starch-to-glucose conversion, reduces enzymatically liberated sugars, and blunts postprandial glycemic response. Through enzymatic downregulation, biogrape™ minimizes glycemic burden, reduces β-cell overstimulation, enhances insulin receptor responsiveness, and mitigates insulin resistance—hallmarks of metabolic syndrome and type 2 diabetes pathogenesis. Additionally, insoluble fibers increase fecal mass and peristaltic velocity, reducing luminal retention of sugars and minimizing mucosal contact duration. The shortened absorption window leads to partial saccharide excretion, directly reducing systemic glucose assimilation. This multi-axis mechanism—integrating protective layer entrapment, enzymatic blockade, and accelerated transit—constitutes a comprehensive glycemic defense system. Unabsorbed   saccharides   are   subsequently fermented   by colonic microbiota into  SCFAs (acetate, propionate, butyrate), which  enhance epithelial (…)